Moderna announced that participants began receiving doses of its experimental HIV vaccine, kicking off phase 1 of its clinical trial.
In a January 28 press release, Moderna said the clinical trial, IAVI G002, is testing whether a two-dose mRNA vaccine can successfully produce “broadly neutralizing antibodies,” a type of antibody that can recognize and block many types of HIV from entering healthy cells.